Clinical Trial Update: Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating chimeric natural killer receptor-universal T cells for relapsed or refractory neuroblastoma. The study is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Chimeric Natural Killer Receptor-Universal T Cells

Snippet

Sponsor: Nanjing Children's Hospital | Conditions: Neuroblastoma, Recurrent, Refractory | Phase 1 | Status: RECRUITING